Pig in Uganda smallholder farm

Analysis of the cross-protective response induced by African swine fever virus recombinant vaccine ASFV-G-ΔI177L

The goal of the project is to analyse patterns of cross-protection induced by the African swine fever vaccine ASFV-G-ΔI177L against field isolates that are causing the disease in Africa.

Overview

Recombinant ASFV-G-ΔI177L is a rationally developed African swine fever virus live attenuated vaccine approved for commercial production by the Government of Vietnam.

The ASFV-G-ΔI177L vaccine was developed by genetic manipulation of the highly virulent African swine fever virus Georgia 2010 (ASFV-G) isolate genotype II.

The vaccine has been shown to be safe and efficacious in inducing solid protection against the virulent parental virus ASFV-G as well as another derivative virus isolated in Vietnam in 2019.

Lack of cross-protection among different strains of the African swine fever virus is  generally accepted but has never been systematically analysed.

Therefore, this project aims to identify the patterns of cross-protection and immune mechanism elicited by the ASFV-G-ΔI177L vaccine.

Expected outcomes

  • Increased understanding of the protective mechanism induced by other live attenuated African swine fever vaccines.
  • Results on cross-protection induced by the African swine fever vaccine ASFV-G-ΔI177L against field isolates in Africa belonging to different genotypes.
     

Staff

Anna Lacasta

Anna Lacasta

Senior scientist, Animal and Human Health